Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 70 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Left Ventricular Ejection Time Clear all

Conditions: Left Ventricular Dysfunction
Interventions: Use of Eko DUO electronic stethoscope; Device
Lead sponsor: Eko Devices, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,258 participants
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Los Alamitos, California • Washington D.C., District of Columbia • Philadelphia, Pennsylvania

Conditions: Ventricular Ejection Fraction
Interventions: Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Tucson, Arizona • Chicago, Illinois • Washington DC, Maryland + 7 more

Conditions: Heart Failure, Cancer Treatment Induced Left Ventricular Dysfunction
Interventions: Echocardiograms, Electrocardiogram, Symptom Questionnaire, Telephone Follow-Up; Device · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Renal Cell
Interventions: Sorafenib (Nexavar, BAY43-9006); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Maywood, Illinois + 4 more

Conditions: Heart Failure, Congestive Heart Failure
Interventions: Isosorbide Dinitrate, Isosorbide Dinitrate + Hydralazine, Placebo; Drug
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Left Ventricular Dysfunction
Interventions: Impella 5.5 with SmartAssist; Device
Lead sponsor: Abiomed Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Jonesboro, Arkansas • Los Angeles, California • San Diego, California + 15 more

Conditions: Advanced Cancers
Interventions: Nuclear Medicine Cardiac Scan, PET/CT Cardiac Scan; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Heart Failure, Congestive, Dyspnea, Pulmonary Edema
Interventions: Nesiritide; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Heart Failure With Reduced Ejection Fraction
Interventions: Coronary Sinus Lead Revision; Other
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Pulmonary Hypertension Associated With HFpEF
Interventions: TNX-103, Placebo; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 45
States / cities: Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more

Conditions: Ventricular Dysfunction, Left, Ventricular Function, Left, Echocardiography, Ultrasonography, Point-of-Care Systems, Heart Function Tests, Stroke Volume, Federated Learning, Machine Learning, Artificial Intelligence (AI), Deep Learning, Neural Networks, Computer, Image Interpretation, Computer-Assisted, Diagnosis, Computer-Assisted, Sensitivity and Specificity, ROC Curve
Interventions: Focused Cardiac Point-of-Care Ultrasonography, FL-POCUS Federated Machine-Learning Analysis System; Diagnostic Test · Device
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Heart Failure
Interventions: Tc99m-Maraciclatide; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Heart Failure, Reduced Ejection Fraction
Interventions: sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more

Conditions: Non-obstructive Hypertrophic Cardiomyopathy
Interventions: mavacamten, Placebo; Drug
Lead sponsor: MyoKardia, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 32
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 28 more

Conditions: Heart Failure
Interventions: Iobenguane I -123 Injection, Implantable Cardioverter Defibrillator, Thyroid blocking; Drug · Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 29
States / cities: Birmingham, Alabama • Bakersfield, California • La Mesa, California + 24 more

Conditions: Ventricular Ejection Fraction
Interventions: Anumana Low EF AI-ECG Algorithm, Care-as-Usual; Device · Other
Lead sponsor: Anumana, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11,610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more

Conditions: Hypertension, Pulmonary, Heart Failure With Reduced Ejection Fraction
Interventions: Eko CORE 500 Digital Stethoscope; Device
Lead sponsor: Eko Devices, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,850 participants
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: O'Fallon, Illinois • Springfield, Illinois • Norfolk, Virginia

Conditions: Pulmonary Hypertension
Interventions: TNX-103, Placebo; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 40
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 32 more

Conditions: Transthoracic Echocardiography, Suspected or Known Structural or Functional Cardiac Abnormality
Interventions: Optison; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 9 Years to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • Augusta, Georgia + 5 more

Conditions: Chronic Heart Failure
Interventions: LCZ696, Valsartan, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 11
States / cities: Little Rock, Arkansas • Chicago, Illinois • Detroit, Michigan + 8 more

Conditions: Diabetes Mellitus, Type 2, Heart Failure, Diastolic
Interventions: Exenatide; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 30 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Current or Recent History of Atrial Fibrillation
Interventions: bucindolol hydrochloride, metoprolol succinate, Placebo oral capsule; Drug · Other
Lead sponsor: ARCA Biopharma, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 48
States / cities: Anchorage, Alaska • Phoenix, Arizona • East Palo Alto, California + 43 more

Conditions: Left Ventricular Dysfunction, Ventricular Dysfunction, Heart Diseases, Cardiovascular Diseases
Interventions: Use of Eko DUO Electronic Stethoscope; Device
Lead sponsor: Eko Devices, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,935 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: O'Fallon, Illinois • Springfield, Illinois

Conditions: Left Ventricular Ejection Fraction, Heart Failure (HF), Left Bundle-Branch Block
Interventions: LB-CRT, BIV-CRT; Device
Lead sponsor: Inova Health Care Services; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Durham, North Carolina • Falls Church, Virginia

Search by objective public record fields.

Detection of Heart Conditions With Single Lead ECG Using Artificial Intelligence

DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function

REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction

IMpella-Protected cArdiaC Surgery Trial (IMPACT)

Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging

Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF

Conduction System Vs Surgical Left Ventricular Epicardial Pacing For Coronary Sinus Lead Failure

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

Federated Learning for Point-of-Care Cardiac Ultrasound

Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device

A Multicenter Pragmatic Implementation Study of ECG-AI-Based Clinical Decision Support Software to Identify Low LVEF

Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Study to Determine Safety and Dosage of OPTISON in Pediatric Participants

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

Low Ejection Fraction in Single Lead ECG

REsynchronization Comparison In LBBB and Normal or Mildly Reduced VENTricular Function With CRT (REINVENT-CRT)